Is The Santa Claus Rally The Gift That Keeps Giving?
Remember the horror of 2008 when the Great Recession hit…
Sell
22
EOLS Quote, Financials, Valuation and Earnings
Last price:
$10.83
Seasonality move
:
60.49%
Day range:
$10.64 - $10.96
52-week range:
$9.80 - $17.82
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.64x
P/B ratio:
116.64x
Volume:
277.7K
Avg. volume:
588.4K
1-year change:
8.94%
Market cap:
$687M
Revenue:
$202.1M
EPS (TTM):
-$0.90
Analysts' Opinion
-
Consensus RatingEvolus has received a consensus rating of Buy. The company's average rating is a Buy based on 4 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, Evolus has an estimated upside of 115.93% from its current price of $10.85.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $10.85.
Fair Value
-
According to the consensus of 4 analysts, Evolus has 115.93% upside to fair value with a price target of -- per share.
EOLS vs. S&P 500
-
Over the past 5 trading days, Evolus has underperformed the S&P 500 by -10.15% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Evolus does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Evolus has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Evolus reported revenues of $61.1M.
Earnings Growth
-
Evolus has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Evolus reported earnings per share of -$0.30.
Enterprise value:
723.2M
EV / Invested capital:
5.69x
Price / LTM sales:
2.64x
EV / EBIT:
--
EV / Revenue:
2.91x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-28.01x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$173.7M
Return On Assets:
-26.5%
Net Income Margin (TTM):
-22.33%
Return On Equity:
-7724.23%
Return On Invested Capital:
-47.66%
Operating Margin:
-21.36%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $139.6M | $184.7M | $248.3M | $50M | $61.1M | |
| Gross Profit | $81.3M | $129.1M | $173.7M | $34.6M | $42.9M | |
| Operating Income | -$66.5M | -$44.3M | -$36M | -$11.6M | -$13M | |
| EBITDA | -$68.4M | -$44.9M | -$31M | -$11.6M | -$13M | |
| Diluted EPS | -$1.42 | -$1.11 | -$0.90 | -$0.30 | -$0.30 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $132.4M | $138.3M | $115.9M | $92M | $150.4M | |
| Total Assets | $215.8M | $215.2M | $192.7M | $168M | $229.6M | |
| Current Liabilities | $12.7M | $71.3M | $51.3M | $48.5M | $60.8M | |
| Total Liabilities | $180.7M | $117.8M | $163.5M | $187.3M | $223.7M | |
| Total Equity | $35.1M | $97.4M | $29.2M | -$19.4M | $5.9M | |
| Total Debt | $133M | $20M | $71.7M | $95.1M | $121.2M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$85.2M | -$43.6M | -$22M | -$924K | -$5.7M | |
| Cash From Investing | -$1.9M | -$2.7M | -$3.8M | -$539K | -$1.4M | |
| Cash From Financing | $45.3M | $19.6M | $72.2M | -$1.4M | -$1.4M | |
| Free Cash Flow | -$87.1M | -$46.3M | -$25.8M | -$1.5M | -$7.1M | |
EOLS
Sector
Market Cap
$687M
$46.1M
Price % of 52-Week High
60.89%
46.02%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.6%
1-Year Price Total Return
8.94%
-30.52%
Beta (5-Year)
1.266
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$11.16
200-day SMA
Sell
Level
$13.52
Bollinger Bands (100)
Sell
Level
12.67 - 16.55
Chaikin Money Flow
Sell
Level
-72.5M
20-day SMA
Sell
Level
$12.12
Relative Strength Index (RSI14)
Sell
Level
28.02
ADX Line
Sell
Level
25.65
Williams %R
Buy
Level
-90.678
50-day SMA
Sell
Level
$13.76
MACD (12, 26)
Sell
Level
-0.79
25-day Aroon Oscillator
Sell
Level
-64
On Balance Volume
Neutral
Level
35.2M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-1.7545)
Sell
CA Score
(Annual)
Level (-3.5268)
Buy
Beneish M-Score
(Annual)
Level (-3.0106)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (5.9634)
Buy
Piotroski F Score
(Annual)
Level (7)
Buy
Quality Ratio Score
Level (7)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.
Stock Forecast FAQ
In the current month, EOLS has received 4 Buy ratings 0 Hold ratings, and 0 Sell ratings. The EOLS average analyst price target in the past 3 months is --.
-
Where Will Evolus Stock Be In 1 Year?
According to analysts, the consensus estimate is that Evolus share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Evolus?
Analysts are divided on their view about Evolus share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Evolus is a Sell and believe this share price will drop from its current level to --.
-
What Is Evolus's Price Target?
The price target for Evolus over the next 1-year time period is forecast to be -- according to 4 Wall Street analysts, 4 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is EOLS A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Evolus is a Buy. 4 of 4 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of EOLS?
You can purchase shares of Evolus via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Evolus shares.
-
What Is The Evolus Share Price Today?
Evolus was last trading at $10.83 per share. This represents the most recent stock quote for Evolus. Yesterday, Evolus closed at $10.85 per share.
-
How To Buy Evolus Stock Online?
In order to purchase Evolus stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 118x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Alerts
Buy
87
PSIX alert for Dec 25
Power Solutions International [PSIX] is up 27.42% over the past day.
Buy
65
TSLL alert for Dec 25
Direxion Daily TSLA Bull 2X Shares [TSLL] is up 19.46% over the past day.
Buy
75
SMLR alert for Dec 25
Semler Scientific [SMLR] is up 15.37% over the past day.
